Rani Therapeutics Holdings, Inc. - Class A Common Stock

Share · US7530181004 · RANI (XNAS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Rani Therapeutics Holdings, Inc. - Class A Common Stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

29.04.2026 11:24

Current Prices from Rani Therapeutics Holdings, Inc. - Class A Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	RANI	USD	29.04.2026 11:24	0,85 USD	-0,02 USD -2,05 %
IEX	RANI	USD	28.04.2026 19:58	0,87 USD	-0,02 USD -2,69 %

Share Float & Liquidity

Free Float 72,16 %

Shares Float 47,14 M

Shares Outstanding 65,32 M

Company Profile for Rani Therapeutics Holdings, Inc. - Class A Common Stock Share

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.